The next few years are going to seriously challenge the skills of H. Lundbeck’s (OTCPK:HLUYY)
(LUN.KO) recently-hired CEO Deb Dunsire and head of R&D Johan
Luthman, as the company has to contend with serious erosion in its
mature portfolio, a very weak late-stage pipeline (not to mention risky
early-stage assets), and the challenges that go with M&A and
in-licensing. While Lundbeck does head into this difficult period with
some strong drugs still early in their commercialization and a very
clean balance sheet, investors need only look at Roche (OTCQX:RHHBY) to see how the market treats pharma companies with sluggish near-term EPS growth prospects.
Click here for more:
Lundbeck Entering A Period Of Heightened Uncertainty
No comments:
Post a Comment